+ General Considerations
- Histologic types: leiomyosarcoma, FSA, undifferentiated sarcoma, liposarcoma, OSA, CSA, myxosarcoma, rhabdomyosarcoma, and fibrous histiocytoma
- Clinical signs: inappetence, abdominal distension, polydipsia, lethargy, vomiting, weight loss, and weakness
- Abdominal mass frequently detected with abdominal palpation and survey abdominal radiographs
- Treatment: splenectomy
- Prognosis is guarded to poor with overall MST 10 weeks
- MST 1 month for dogs with evidence of metastatic disease at surgery
- MST 9 months for dogs with no evidence of metastatic disease at surgery
+ Splenic Nodular Hyperplasia
- Splenic nodular hyperplasia can be classified according to type and proportion of cellular components:
- Lymphoid
- Hematopoietic
- Plasmocytic
- Fibrohistiocytic
- Mixed
+ Nodular Fibrohistiocytic Hyperplasia
- Nodular fibrohistiocytic hyperplasia may represent a transitional form between nodule and malignant neoplasia (i.e., malignant fibrous histiocytoma or generalized histiocytic sarcoma)
- Nodular fibrohistiocytic proliferation in canine spleen characterized by a mixed population of spindle cells in varying proportions with hematopoietic elements, plasma cells, and lymphocytes
- MST 5.0-5.5 months, with 12-month survival rate 48%
- 44% of deaths directly attributable to splenic disease
- Poor prognostic factors include low lymphoid-to-fibrohistiocytic ratio and high mitotic index
+ Survival
- 0-9 cells per 10 high power fields
- 12-month survival rate 40%
- greater than 9 cells per 10 high power fields
- MST 1 month